查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425010

急性淋巴母細胞白血病治療市場，按應用、按藥物、按國家和地區分類 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Acute Lymphoblastic Leukemia Therapeutics Market, By Application, By Drug, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 277 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年，急性淋巴母細胞白血病治療市場規模為37.942億美元，2023年至2030年CAGR為5.7%。

急性淋巴母細胞白血病治療市場-市場動態

急性淋巴細胞白血病發病率的增加和全球骨髓活體組織切片的激增預計將推動市場需求

由於急性淋巴細胞白血病發病率的增加和全球骨髓活體組織切片的激增，該市場成長。此外，對白血病研究的投資增加以及人們對標靶治療的認知不斷提高推動市場擴張。然而，嚴格的法規核准和不良藥物副作用帶來了挑戰。關鍵治療藥物的專利到期和治療成本上升也限制了市場成長。儘管如此，不斷增加的臨床試驗和新產品批准為新興和已開發市場提供了機會。

急性淋巴母細胞白血病治療市場 - 關鍵見解

根據研究分析師的分析，全球急性淋巴母細胞白血病治療市場預計在預測期內（2023-2030）每年將以 5.7%左右的CAGR成長

由於急性淋巴母細胞白血病發病率增加和全球骨髓活體組織切片激增，預計急性淋巴性白血病治療市場將以顯著速度成長

根據應用，兒科領域預計在2022年顯示最大的市場佔有率

基於藥物，Hyper-CVAD 療法是2022年的領先細分市場

依地區分類，北美是2022年的主要收入來源

急性淋巴母細胞白血病治療市場-細分分析：

全球急性淋巴母細胞白血病治療市場根據應用、藥物和地區進行細分。

根據應用，市場分為兩個部分：兒科和成人。兒科部門產生了最高的收入，預計在整個預測期內將保持領先地位。這主要歸因於兒科族群中急性淋巴球/淋巴球白血病的發生率增加。急性淋巴性/淋巴性白血病是兒科族群中最常見的癌症類型之一。此外，兒科患者在急性淋巴細胞/淋巴細胞白血病治療中表現出更高的成功率，進一步鞏固了該領域的主導地位。

市場依藥物分為六個部分：Hyper-CVAD 方案、Linker 方案、核苷代謝抑制劑（如 Clolar 和 Nelarabine）、標靶藥物和免疫療法、CALGB 8811 方案和 Oncaspar。其中，Hyper-CVAD 方案由於其在 ALL 治療中的廣泛應用，在2022年成為急性淋巴細胞/淋巴細胞白血病治療市場的主導者。 Hyper-CVAD 方案廣泛認為是急性淋巴性/淋巴球白血病最常用的治療選擇之一。

急性淋巴母細胞白血病治療市場-地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲地區。這些區域根據開展業務的國家進一步分類。

急性淋巴母細胞白血病治療市場-競爭格局：

急性淋巴母細胞白血病治療領域的公司積極從事研究和開發，以推進治療選擇。他們投資於發現針對 ALL 特定方面的新藥和療法，目的是提高療效並減少副作用。與醫療機構和學術研究中心的合作促進了臨床試驗和創新療法的發展。也致力於提高這些治療的可近性和可負擔性，特別是在新興市場。此外，公司優先考慮監管批准並遵守嚴格的品質標準，以確保患者安全。總體而言，他們的目標是繼續發展 ALL 療法的前景，為與這種具有挑戰性的疾病作鬥爭的患者帶來希望和更好的結果。

最近的發展：

2023年5月，總部位於美國和愛爾蘭的製藥公司Shorla Oncology與生命科學領域領先的商業化服務供應商EVERSANA合作，正式啟動Nelarabine注射液的商業上市。該藥物目的是治療未出現陽性反應的成人和一歲及以上兒童患者的 T 細胞急性淋巴母細胞白血病（T-ALL）和 T 細胞淋巴細胞淋巴瘤（T-LBL），或在至少兩種化療方案治療後出現復發。

目錄

第1章 急性淋巴母細胞白血病治療市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘要
    • 依應用分類的急性淋巴母細胞白血病治療市場摘要
    • 依藥物分類的急性淋巴母細胞白血病治療市場摘要
    • 依國家分類的急性淋巴母細胞白血病治療市場摘要
    • 依地區分類的急性淋巴母細胞白血病治療市場摘要
  • 競爭洞察

第3章 急性淋巴母細胞白血病治療主要市場趨勢

  • 急性淋巴母細胞白血病治療市場促進因素
    • 市場促進因素的影響分析
  • 急性淋巴母細胞白血病治療市場限制
    • 市場限制影響分析
  • 急性淋巴母細胞白血病治療市場機會
  • 急性淋巴母細胞白血病治療市場未來趨勢

第4章 急性淋巴母細胞白血病治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 急性淋巴母細胞白血病治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 急性淋巴母細胞白血病治療市場格局

  • 2022年急性淋巴母細胞白血病治療市佔分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章 急性淋巴母細胞白血病治療市場 -依應用

  • 概述
    • 依應用的細分市場佔有率分析
    • 兒科
    • 成年人

第8章 急性淋巴母細胞白血病治療市場 - 依藥物

  • 概述
    • 依藥物分類的細分市場佔有率分析
    • 超級 CVAD 方案
    • 連接器方案
    • 核苷代謝抑制劑（Clolar 和 Nelarabine）
    • 標靶藥物和免疫治療
    • CALGB 8811 方案
    • 翁卡斯帕

第9章 急性淋巴母細胞白血病治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美急性淋巴母細胞白血病治療主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依應用）
    • 北美市場規模和預測（依藥物）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲急性淋巴母細胞白血病治療藥物主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依應用）
    • 歐洲市場規模與預測（按藥品）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區急性淋巴母細胞白血病治療主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依應用）
    • 亞太地區市場規模與預測（依藥物）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲急性淋巴母細胞白血病治療主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依應用）
    • 拉丁美洲市場規模與預測（按藥品）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲急性淋巴母細胞白血病治療主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依應用）
    • 中東和非洲市場規模及預測（按藥品）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA的其他地區

第10章 主要供應商分析-急性淋巴母細胞白血病治療產業

  • 競爭儀表板
  • 公司簡介
    • Amgen, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Erytech Pharma, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Kite Pharma, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Spectrum

第11章 360 度分析師視角

第12章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV2210

REPORT HIGHLIGHT

Acute Lymphoblastic Leukemia Therapeutics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Acute Lymphoblastic Leukemia Therapeutics Market- Market Dynamics

Increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies is expected to propel the market demand

The market is witnessing growth due to the increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies. Additionally, heightened investments in leukemia research and growing awareness of targeted therapies among the population are driving market expansion. However, stringent regulatory approvals and adverse drug side effects pose challenges. Patent expirations of key treatment drugs and elevated therapy costs also limit market growth. Nonetheless, increasing clinical trials and new product approvals offer opportunities in emerging and developed markets.

Acute Lymphoblastic Leukemia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Acute Lymphoblastic Leukemia Therapeutics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Acute Lymphoblastic Leukemia Therapeutics Market is projected to grow at a significant rate driven by increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies

Based on Application, the pediatrics segment was predicted to show maximum market share in the year 2022

Based on Drug, Hyper -CVAD Regimen was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Acute Lymphoblastic Leukemia Therapeutics Market- Segmentation Analysis:

The Global Acute Lymphoblastic Leukemia Therapeutics Market is segmented on the basis of Application, By Drug, and Region.

Based on the application, the market is divided into two segments: pediatrics and adults. The pediatrics segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. This is primarily attributed to the elevated incidence of acute lymphocytic/lymphoblastic leukemia among the pediatric population. Acute lymphocytic/lymphoblastic leukemia ranks as one of the most prevalent cancer types in the pediatric demographic. Furthermore, pediatric patients exhibit a higher success rate in acute lymphocytic/lymphoblastic leukemia treatments, further solidifying the segment's dominance.

The market is categorized by Drug into six segments: Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (such as Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Among these, the Hyper-CVAD Regimen emerged as the dominant player in the acute lymphocytic/lymphoblastic leukemia therapeutics market in 2022 due to its extensive utilization in ALL treatment. The Hyper-CVAD Regimen is widely recognized as one of the most frequently employed therapeutic options for acute lymphocytic/lymphoblastic leukemia.

Acute Lymphoblastic Leukemia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Acute Lymphoblastic Leukemia Therapeutics Market- Competitive Landscape:

Companies in the Acute Lymphoblastic Leukemia therapeutics sector are actively engaged in research and development to advance treatment options. They invest in the discovery of novel drugs and therapies that target specific aspects of ALL, aiming for improved efficacy and reduced side effects. Collaborations with healthcare institutions and academic research centers facilitate clinical trials and the development of innovative treatments. Efforts are also directed towards enhancing the accessibility and affordability of these treatments, particularly in emerging markets. Furthermore, companies prioritize regulatory approvals and adherence to stringent quality standards to ensure patient safety. Overall, their goal is to continue evolving the landscape of ALL therapeutics, offering hope and better outcomes for patients battling this challenging disease.

Recent Developments:

In May 2023, Shorla Oncology, a pharmaceutical company based in the United States and Ireland, in collaboration with EVERSANA, a leading provider of commercialization services for the life science sector, officially initiated the commercial release of Nelarabine Injection. This drug is intended for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in both adult and pediatric patients aged one year and older who have not experienced a positive response to, or have experienced relapse following treatment with, a minimum of two chemotherapy regimens.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET KEY PLAYERS

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Erytech Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Kite Pharma, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Spectrum

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY APPLICATION

  • Pediatrics
  • Adults

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG

  • Hyper-CVAD Regimen
  • Linker Regimen
  • Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
  • Targeted Drugs & Immunotherapy
  • CALGB 8811 Regimen
  • Oncaspa

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Acute Lymphoblastic Leukemia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Application
    • 2.1.2. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Drug
    • 2.1.3. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Country
    • 2.1.4. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Acute Lymphoblastic Leukemia Therapeutics Key Market Trends

  • 3.1. Acute Lymphoblastic Leukemia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Acute Lymphoblastic Leukemia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Acute Lymphoblastic Leukemia Therapeutics Market Opportunities
  • 3.4. Acute Lymphoblastic Leukemia Therapeutics Market Future Trends

4. Acute Lymphoblastic Leukemia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Acute Lymphoblastic Leukemia Therapeutics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Acute Lymphoblastic Leukemia Therapeutics Market Landscape

  • 6.1. Acute Lymphoblastic Leukemia Therapeutics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Acute Lymphoblastic Leukemia Therapeutics Market - By Application

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 7.1.2. Pediatrics
    • 7.1.3. Adults

8. Acute Lymphoblastic Leukemia Therapeutics Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
    • 8.1.2. Hyper-CVAD Regimen
    • 8.1.3. Linker Regimen
    • 8.1.4. Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
    • 8.1.5. Targeted Drugs & Immunotherapy
    • 8.1.6. CALGB 8811 Regimen
    • 8.1.7. Oncaspa

9. Acute Lymphoblastic Leukemia Therapeutics Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Acute Lymphoblastic Leukemia Therapeutics Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Amgen, Inc.
    • 10.2.2. Bristol-Myers Squibb Company
    • 10.2.3. Celgene Corporation
    • 10.2.4. Erytech Pharma, Inc.
    • 10.2.5. F. Hoffmann-La Roche Ltd.
    • 10.2.6. Kite Pharma, Inc.
    • 10.2.7. Novartis AG
    • 10.2.8. Pfizer Inc.
    • 10.2.9. Sanofi
    • 10.2.10. Spectrum

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Application 2018-2030 (USD Million)
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Drug Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Drug 2018-2030 (USD Million)
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)

List of Figures

  • FIGURE Acute Lymphoblastic Leukemia Therapeutics Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Application segment market share analysis, 2022 & 2030
  • FIGURE Application segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Drug segment market share analysis, 2022 & 2030
  • FIGURE Drug segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Europe Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Germany Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE India Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Brazil Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Saudi Arabia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)